Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: open issues and future directions

Bone Marrow Transplantation volume 35, pages S23–S26 (2005)Cite this article

Summary:

For the past two decades, hematopoietic cell transplantation (HCT) has been used as effective therapy for selected inherited metabolic diseases (IMD). The primary goals of this therapy have been to promote long-term survival with donor-derived engraftment and to optimize quality of life. Careful, multidisciplinary decision-making regarding whether to recommend HCT and how to provide optimal peri- and post-HCT care has proven essential to increase the likelihood of a good outcome. Guidelines for HCT and monitoring have recently been provided in this journal. Here we report data on transplant activity for IMD in Europe and briefly discuss future directions. It is imperative that data collection for these procedures becomes as routine as that for patients undergoing HCT for malignancy and that follow-up is performed in a systematic manner. Large clinical trials have never been performed in this transplant field. Fortunately, accreditation procedures and improvements in information technology can now provide a firm foundation for such trials, which are urgently needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Peters C, Steward CG . Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229–239.

    Article  CAS  PubMed  Google Scholar 

  2. Peters C, Balthazor M, Shapiro EG et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894–4902.

    CAS  PubMed  Google Scholar 

  3. Peters C, Shapiro EG, Anderson J et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998; 91: 2601–2608.

    CAS  PubMed  Google Scholar 

  4. Souillet G, Guffon N, Maire I et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone marrow Transplant 2003; 31: 1105–1117.

    Article  CAS  PubMed  Google Scholar 

  5. Peters C, Charnas LR, Tan Y, Ziegler RS et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104: 881–888.

    Article  CAS  PubMed  Google Scholar 

  6. Grewal SS, Krivit W, Defor TE et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone marrow Transplant 2002; 29: 491–496.

    Article  CAS  PubMed  Google Scholar 

  7. Wraith JE, Clarke LA, Beck M, Kolodny EH et al. Enzyme replacement therapy for mucopolysaccharidosis. I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144: 581–588.

    Article  CAS  PubMed  Google Scholar 

  8. Ellinwood NM, Vite CH, Haskins ME . Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004; 6: 481–506.

    Article  CAS  PubMed  Google Scholar 

  9. Biffi A, De Palma M, Quattrini A et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest 2004; 113: 1118–1129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Herzog EL, Chai L, Krause DS . Plasticity of marrow-derived stem cells. Blood 2003; 102: 3483–3493.

    Article  CAS  PubMed  Google Scholar 

  11. O'Malley K, Scott EW . Stem cell fusion confusion. Exp Hematol 2004; 32: 131–134.

    Article  PubMed  Google Scholar 

  12. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215–222.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Giorgio Dini and Maarten Egeler for providing a specific session for discussion of IMD at this meeting, and for encouraging us to review the available EBMT data. We hope that this review has laid a foundation for important future developments in this widely neglected area of HCT.

Author information

Authors and Affiliations

  1. BMT Unit, Paediatric Department of Milano-Bicocca University, San Gerardo Hospital, Monza, Italy

    A M Rovelli

  2. BMT Unit, Royal Hospital for Children, Bristol, UK

    C G Steward

Authors
  1. A M Rovelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C G Steward
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A M Rovelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rovelli, A., Steward, C. Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: open issues and future directions. Bone Marrow Transplant 35 (Suppl 1), S23–S26 (2005). https://doi.org/10.1038/sj.bmt.1704839

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704839

Keywords

This article is cited by

Search

Advanced search

Quick links